AUSTIN, Texas, April 12, 2016 -- SmallCapVoice.com, Inc. (SCV) and Advanced Medical Isotope Corporation (or "AMI") (OTC:ADMD), (www.IsotopeWorld.com) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/4-11-16-smallcapvoice-interview-with-advanced-medical-isotope-corporation-admd.
AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Alice Villalobos, DVM, FNAP, Company chairperson of AMI’s new Veterinary Medicine Advisory Board called in to SmallCapVoice.com, Inc. to go over the exciting new markets and news for the Company. Recently ADMD announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.
"The companion animal market is an area that we believe AMI will excel in. I believe that our products have great potential to enhance the quality of life for pets, an outcome that should be quite gratifying as well as a significant revenue source for the Company," stated Katzaroff.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About Advanced Medical Isotope Corporation:
Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
Safe Harbor Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACTS: Advanced Medical Isotope Corporation James C. Katzaroff, CEO 1021 N Kellogg Kennewick WA 99336 509-736-4000 Investor Relations Tyler M. Troup, B.Comm Circadian Group IR, Managing Director info@Circadian-Group.com 866-950-8300 For SmallCapVoice.com Stuart T. Smith 512-267-2430 email@example.com